SBFM on Nasdaq

Sunshine Biopharma Inc.

American pharmaceutical preparations company based in Pointe-Claire. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with LFTD PARTNERS INC., Earth Science Tech, Inc. or Verrica Pharmaceuticals Inc., or pick any stock.

  • TickerSBFM on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersNew York, United States2
  • Incorporated inCO3
  • Business address333 Las Olas Way, Cu4 Suite 433, Fort Lauderdale, Fl 333013
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI5299005Y64EHRQDQ2Q252
  • StatusActive2
  • LEI statusIssued and current2
  • Registered addressc/o Evans Case, LLP, 1660 S Albion St Ste 110, 80222 Denver, United States2
  • Registered withBusiness Division of the Secretary of State’s office, 200613584312

See how the biggest companies compare on our leaderboards

In-licensing and Supply Agreements: Nora Pharma acquires the rights to import, market, sell and distribute the products in Canada by purchasing the drug dossiers from strategic partners. Nora Pharma then files the dossiers with Health Canada to obtain regulatory approval prior to marketing. The approval process at Health Canada takes on average of 12 months. The products are sold under Nora Pharma label.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

33.8%Gross margin5
-17.2%Operating margin5
-16.5%Net margin5
4.1%Revenue growth, 20255
-25.9%Return on equity5
-$5.5MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue66¢$24.1M
  • Research and development2¢$604.3K
  • Other costs32¢$11.6M
  • Income tax0¢$21.6K

Out of $36.3M in revenue.5 The company lost money this year.

Financial statements

Revenue6789105$36.3M in 2025+171795% since 2019
0$10.0M$20.0M$30.0M$40.0M2019: $21.1K$21.1K20192020: $71.4K$71.4K2020+238%2021: $228.4K$228.4K2021+220%2022: $4.3M$4.3M2022+1802%2023: $24.1M$24.1M2023+454%2024: $34.9M$34.9M2024+45%2025: $36.3M$36.3M2025+4%
Gross profit6789105$12.3M in 2025+121593% since 2019
0$5.0M$10.0M$15.0M2019: $10.1K$10.1K20192020: $45.6K$45.6K2020+352%2021: $110.6K$110.6K2021+143%2022: $1.7M$1.7M2022+1434%2023: $8.3M$8.3M2023+392%2024: $10.7M$10.7M2024+28%2025: $12.3M$12.3M2025+15%
Operating income6789105-$6.2M in 2025+870% since 2019
-$30.0M-$20.0M-$10.0M02019: -$641.6K-$641.6K20192020: -$576.9K-$576.9K2020−10%2021: -$2.4M-$2.4M2021+323%2022: -$27.0M-$27.0M2022+1007%2023: -$4.8M-$4.8M2023−82%2024: -$5.8M-$5.8M2024+21%2025: -$6.2M-$6.2M2025+7%
Net income6789105-$6.0M in 2025+260% since 2019
-$30.0M-$20.0M-$10.0M02019: -$1.7M-$1.7M20192020: -$2.8M-$2.8M2020+68%2021: -$12.4M-$12.4M2021+347%2022: -$26.7M-$26.7M2022+115%2023: -$4.5M-$4.5M2023−83%2024: -$5.1M-$5.1M2024+14%2025: -$6.0M-$6.0M2025+16%

Every line of the income statement as filed: the last 2 fiscal years, latest first.5

Period ending2025-12-312024-12-31
Revenue:$36.3M$34.9M
Cost of Sales$24.1M$24.2M
Gross profit$12.3M$10.7M
Accounting$698.1K$967.6K
Consulting$1.6M$925.2K
Director fees$400.0K$400.0K
Intangible assets impairment$1.7M$0
Legal$385.1K$875.7K
Marketing$1.1M$940.3K
Office$3.9M$3.1M
R&D$604.3K$933.9K
Salaries$7.3M$7.7M
Taxes$469.3K$387.0K
Depreciation & amortization$332.1K$223.5K
Total General & Administrative Expenses$18.5M$16.5M
(Loss) from operations-$6.2M-$5.8M
Foreign exchange gain (loss)$2.6K-$44.1K
Interest income$280.9K$496.0K
Interest expense$0-$8.8K
Gain (Loss) on asset sale-$10.3K$0
Total Other Income (Expense)$273.3K$443.1K
Net (loss) before income taxes-$6.0M-$5.4M
Provision for income taxes$21.6K-$234.9K
Net (Loss)-$6.0M-$5.1M
Gain (Loss) from foreign exchange translation$764.6K-$1.5M
Comprehensive (Loss)-$5.2M-$6.7M
(Loss) per common share, Basic-$1.44-$7.32
Weighted average common shares outstanding, Basic4.2M shares701.7K shares

Compare Sunshine Biopharma Inc. with another company

Leadership

Who has led Sunshine Biopharma Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Steve N. Slilaty2009–2024

President

  1. Steve N. Slilaty2009

Chief financial officer

  1. Camille Sebaaly2009–2022

Chief operating officer

  1. Turi Michele Di2009–2015
  2. Abderrazzak Merzouki2015–2021
  3. Marc Beaudoin2024
2010201520202025
Board members and other officers (10)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorAndrew N. Keller named Mar 18, 2022 to May 17, 202324
  • DirectorRabi N. Kiderach named May 17, 202324

Former names

  • Sunshine Biopharma, IncNov 6, 2009 to Oct 17, 20243
  • Mountain West Business Solutions, IncNov 5, 2007 to Nov 2, 20093
  • mountain west business solutions,incOct 19, 2007 to Oct 19, 20073
  • mountain state business solutions,incMay 25, 2007 to May 25, 20073

Timeline

  1. Nov 2, 2009New chief executive Steve N. Slilaty becomes CEO13
  2. Aug 31, 2006Founded Sunshine Biopharma Inc. is founded2

Filings

223 filings to the SEC since October 2021: 5 annual reports, 16 quarterly reports, 68 major events, 15 insider forms, 18 large holders, 3 private raises, 98 other. The latest 20:

  1. Oct 14, 2026SCHEDULE 13G EDGAR
  2. Oct 14, 2026PRE 14C PRELIMINARY INFORMATION STATEMENT EDGAR
  3. Oct 14, 20268-K CURRENT REPORT EDGAR
  4. Oct 13, 2026SCHEDULE 13G EDGAR
  5. Oct 9, 20268-K CURRENT REPORT EDGAR
  6. Oct 9, 2026424B4 PROSPECTUS EDGAR
  7. Oct 7, 2026EFFECT EDGAR
  8. Oct 5, 2026SCHEDULE 13G/A EDGAR
  9. Oct 2, 2026S-1 EDGAR
  10. Sep 28, 2026DEF 14C DEFINITIVE INFORMATION STATEMENT EDGAR
  11. Sep 24, 2026DRS EDGAR
  12. Sep 16, 2026PRE 14C PRELIMINARY PROXY EDGAR
  13. Sep 16, 20268-K EDGAR
  14. Sep 11, 20268-K EDGAR
  15. Sep 8, 2026EFFECT EDGAR
  16. Sep 8, 2026424B3 EDGAR
  17. Aug 28, 2026S-1 EDGAR
  18. Aug 28, 20268-K CURRENT REPORT EDGAR
  19. Aug 14, 2026SCHEDULE 13G/A EDGAR
  20. Aug 13, 202610-Q FORM 10-Q FOR JUN 2026 EDGAR

The 223 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

4 open-market trades by officers, directors and large owners since October 2021: 4 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Mar 4, 2024Slilaty Steve N.Chief Executive OfficerBuy100,000$0.10$10.0KForm 4
Feb 8, 2024Slilaty Steve N.Chief Executive OfficerBuy20,000$0.10$2.0KForm 4
Nov 30, 2022Sebaaly CamilleCFO/SecretaryBuy30,000$0.76$22.8KForm 4
Jun 3, 2022Sebaaly CamilleCFO/SecretaryBuy25,000$1.22$30.5KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. May 12, 2023Raised $5 million in a private offering of equity Form D: 1 investor so far Form D
  2. Apr 25, 2022Raised $19.5 million in a private offering of equity Form D: 9 investors so far Form D
  3. Mar 10, 2022Raised $8 million in a private offering of equity Form D: 9 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Jane Street Group, LLC14,974$31.4K0.0%New
Morgan Stanley385$8080.0%New
SBI Securities Co., Ltd.162$3400.0%New
National Bank Of Canada /fi/5$100.0%New
Osaic Holdings, Inc.2$40.0%New
Caitong International Asset Management Co., Ltd1$20.0%New
Farther Finance Advisors, LLC1$20.0%New
TD Waterhouse Canada Inc.1$20.0%New
Strive Financial Group ,LLC1$20.0%New

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

1 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Jun 30, 2022Roger WilliamsRepublican, HouseBuy$1,001 - $15,000−204.6%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33